Compare OIS & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OIS | CMPS |
|---|---|---|
| Founded | 1995 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.3M | 598.7M |
| IPO Year | 2001 | 2020 |
| Metric | OIS | CMPS |
|---|---|---|
| Price | $7.10 | $6.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $6.50 | ★ $16.43 |
| AVG Volume (30 Days) | 619.7K | ★ 1.6M |
| Earning Date | 10-31-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $655,119,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $18.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $2.25 |
| 52 Week High | $7.19 | $7.13 |
| Indicator | OIS | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 66.43 |
| Support Level | $6.63 | $4.90 |
| Resistance Level | $7.19 | $5.57 |
| Average True Range (ATR) | 0.24 | 0.38 |
| MACD | 0.08 | 0.20 |
| Stochastic Oscillator | 93.50 | 84.53 |
Oil States International Inc is a provider of manufactured products and services to the energy, industrial and military sectors. Manufactured products include engineered capital equipment as well as products consumed in the drilling, well construction and production of oil and natural gas. The company sells its products and services to national oil and natural gas companies, oil and natural gas companies, onshore and offshore drilling companies and other oilfield services, defense and industrial companies. The company operates through three business segments, Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. It gains maximum revenue from Offshore Manufactured Products.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.